Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaxaplin in proteinuric APOL1-mediated kidney disease
NCT06794996Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inaxaplin in APOL1-mediated kidney disease (AMKD), sponsored by Vertex Pharmaceuticals. Primary endpoint: Urine Albumin-Creatinine Ratio at 13 weeks. Started Feb 2025; status: completed.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NCT06794996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794996.